

RubrYc Therapeutics Winner of the 2018 Xcelerate Startup Pitch Competition

Boston, Massachusetts, September 6, 2018 – RubrYc Therapeutics, Inc., a biotherapeutics discovery business, announced today it was selected the winner of the 2018 Xcelerate Startup Pitch Competition held September 5, 2018, as part of Biotech Week Boston.

“I am honored to be recognized amongst such a strong field of promising biotech startups from around the world,” said Dr. Isaac Bright, CEO of RubrYc Therapeutics. “This award further validates the utility of our antibody discovery platform to identify high-value therapeutic candidates in oncology and autoimmune disease areas.”

RubrYc Therapeutics is focused on improving drug discovery through proprietary insights into critical interactions at the drug/target interface. Using diverse chemical libraries developed and supplied by HealthTell, Inc., RubrYc is training algorithms that inform improved decision-making throughout drug discovery. The company collaborates with biotechnology companies in early drug discovery and develops its own pipeline of therapeutic antibodies.

“At RubrYc, we are excited to be off to a promising start and are looking forward to our fund raising over the coming year as we drive towards clinical development of our internal programs,” said Dr. Bright.

About RubrYc Therapeutics

Founded in 2017, RubrYc Therapeutics, Inc. emerged as a biotherapeutic discovery partner of immunomics leader HealthTell, Inc. RubrYc Therapeutics is a discovery-stage therapeutic antibody business focused on addressing unmet needs in Oncology and Autoimmune Diseases. The Company was founded in 2017 and launched earlier this year with a \$10M Series A Preferred financing. RubrYc has developed the Interface Discovery Engine – the operating system the Company employs to realize critical efficiency gains in drug discovery.

Contact:

Isaac J. Bright, MD
CEO
RubrYc Therapeutics, Inc.
2420 Camino Ramon
Suite 125
San Ramon, CA 94583
info@rubryc.com